Previous 10 | Next 10 |
JERSEY CITY, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Nkechi Azie, SCYNEXIS’s VP of Clinical Devel...
SCYNEXIS (NASDAQ: SCYX ): FY GAAP EPS of -$0.96 misses by $0.10 . More news on: SCYNEXIS, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Oral ibrexafungerp continues to advance in multiple indications Nearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection; second of two studies (VANISH-306) has complete...
SCYNEXIS ( SCYX +1.4% ) has completed the enrollment of 455 subjects in a second Phase 3 clinical trial, VANISH-306 , evaluating ibrexafungerp, a broad spectrum antifungal, for the treatment of women with vaginial yeast infections. More news on: SCYNEXIS, Inc., Healthcare stocks news,...
JERSEY CITY, N.J. , Feb. 13, 2020 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in its global Phase 3 VANISH...
Today, we will be studying why Scynexis ( SCYX ) is an attractive investment for 2020. Company overview Scynexis is a clinical-stage biopharmaceutical company focused on the development of innovative anti-infective therapies. The company's lead asset, I brexafungerp , is currently being ...
Results from the second interim analysis, a cohort of 21 subjects, of a Phase 3 clinical trial, FURI , evaluating SCYNEXIS' ( SCYX ) oral antifungal ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal infections that are refractory t...
JERSEY CITY, N.J. , Jan. 8, 2020 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from its second interim efficacy analysis of the ongoing P...
JERSEY CITY, N.J. , Dec. 16, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of accomplished business development executive Philip...
JERSEY CITY, N.J. , Dec. 12, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX) today announced the closing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock. Each share...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...